GLUE – monte rosa therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations [Yahoo! Finance]
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results [Yahoo! Finance]
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
Form 8-K Monte Rosa Therapeutics, For: Dec 16
Form SCHEDULE 13G/A Monte Rosa Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Form SCHEDULE 13G/A Monte Rosa Therapeutics, Filed by: Avoro Capital Advisors LLC
Form SCHEDULE 13D/A Monte Rosa Therapeutics, Filed by: Versant Venture Capital VI, L.P.
Form 10-Q Monte Rosa Therapeutics, For: Sep 30
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.